Received May 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MEN | MENINGOCOCCAL (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | U8375AA | OT / LA |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | OT |
MENQUADFI was reconstituted with an MMR Varicella vaccine's diluent and was given to a patient with no AE; Initial information received on 13-May-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 12 years old male patient who received meningococcal A-C-Y-W135 (T CONJ) vaccine [Menquadfi] was reconstituted with measles vaccine;mumps vaccine;rubella vaccine;varicella zoster vaccine diluent with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (TDAP) and HPV vaccine both for Immunisation. On 13-May-2025, the patient received 0.5 ml of dose 1 of meningococcal A-C-Y-W135 (T CONJ) vaccine Solution for injection (strength- standard, expiry date- 30-APR-2028 and lot U8375AA) once via intramuscular route in the left deltoid for Immunization was reconstituted with measles vaccine;mumps vaccine;rubella vaccine;varicella zoster vaccine not produced by Sanofi Pasteur (formulation, strength, expiry date and lot number not reported) diluent with no reported adverse event (product preparation error) (latency- same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
TDAP; HPV VACCINE